Growth Hormone & IGF · Source-reviewed dossier
CJC-1295 (without DAC) + Ipamorelin Blend
Source-Reviewed Research Dossier
This catalog item is a two-component research blend. It pairs a short-acting GHRH analogue that acts at the pituitary with an ipamorelin-type molecule that acts through the ghrelin receptor. Researchers study these two kinds of molecule because they represent separate control points on growth-hormone signalling. The human evidence for ipamorelin is a trial in hospitalized bowel-surgery patients who received it intravenously; the main outcome was not significantly better than placebo. The CJC-related evidence is analytical detection in seized powders, not a health effect. No controlled study of this exact mixture was identified, so its stability and combined behaviour are uncharacterized. For research use only.
Compound overview
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
- Product type
- Multi-component research blend
- Catalog family
- CJC-1295 (without DAC) + Ipamorelin Blend
- Research category
- Growth Hormone & IGF
- Identity boundary
- No single CAS, formula, sequence or molecular weight applies to the two-component mixture.
- Evidence status
- No controlled trial of the exact blend; component evidence only
- Intended use
- Research, development and manufacturing use only
Literature reference parameters
- Compound or material class
- Modified GRF(1-29) / ipamorelin two-component blendCatalog-family identity
- Evidence scope
- No controlled trial of the exact blend; component evidence onlyDo not generalize beyond the cited model
- Source review
- Primary or authoritative records linked belowChecked 2026-09-01
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
How CJC-1295 (without DAC) + Ipamorelin Blend is studied
A target-to-pathway view grounded in the linked research records.
Reported research findings
What published studies report about CJC-1295 (without DAC) + Ipamorelin Blend
Reported outcomes are paired with their experimental model and evidence boundary.
Ipamorelin missed its primary clinical comparison
In a 117-patient postoperative-ileus study, the 25.3 versus 32.6 hour median comparison had p=0.15.
The intravenous protocol does not test this blend or another route.
Read the primary studyModified GHRF-related material has been identified in seized products
Mass-spectrometric work characterized glycine-modified GH secretagogues including modified GRF-related material.
Analytical detection supports identity controls, not safety or efficacy.
Read the primary studyCatalog options
Variant specifications
Pack-level catalog data; lot-level controls remain document-specific.
Specification & documents for CP10
Product specification
Multi-component research blend · 10 mg/vial catalog presentation · 10-vial pack · component identity and ratio controlled by product specification.
Lot documentation
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
Quality documentation
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Interpret the documents, not just the headline number.
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Research context
Published studies and regulatory records, not customer testimonials or usage guidance.
Ipamorelin missed its primary clinical comparison
The intravenous protocol does not test this blend or another route.
View primary recordModified GHRF-related material has been identified in seized products
Analytical detection supports identity controls, not safety or efficacy.
View primary recordCurated references
Third-party publications selected for direct relevance.
-
01
Phase 2
Randomized ipamorelin study after bowel resection
Beck DE, et al. International Journal of Colorectal Disease. 2014. PMID 25331030.
-
02
Analytical study
Glycine-modified growth hormone secretagogues identified in seized doping material
Analytical study. 2019. PMID 30136411.
CJC-1295 (without DAC) + Ipamorelin Blend questions
Concise answers for researchers comparing identity, evidence and catalog variants.
What effects are studied for CJC-1295 (without DAC) + Ipamorelin Blend?
The strongest human record is the ipamorelin phase 2 trial in bowel-resection patients with postoperative ileus. Intravenous ipamorelin was tolerated, but the primary meal-tolerance comparison did not differ significantly from placebo. The CJC-related source identified modified GHRF-type material in seized powders. Neither source documents an effect of this two-component blend, and no controlled study of the exact mixture was found.
How should the CJC-1295 (without DAC) + Ipamorelin Blend research findings be understood?
A catalog blend is a supplied physical mixture, not a characterized formulation. No controlled publication was identified for this exact combination. Co-stability, ratio behaviour and possible interaction between the two components are not established by the supplied references. Component findings belong to their own material, model and route. Lot identity and purity depend on product-specific analytical documents, not blend-level evidence.
What evidence is available for CJC-1295 (without DAC) + Ipamorelin Blend?
Component-level human and analytical records exist, but direct evidence for this combined formulation is absent.
Does the cited research validate this catalog material?
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
Which quality documents can be requested?
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
How should CJC-1295 (without DAC) + Ipamorelin Blend be stored?
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge tools
Continue with structured evidence
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Ready to request a quote?
Selected: CP10 · 10 mg × 10 vials